Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

針對症狀 Prostate Cancer
臨床試驗編號 NCT00065442
臨床階段 Phase III
臨床試驗位址 71 Study Locations
目前研究進度 This study has been completed.
試驗開始日期 July 23, 2003
試驗開始日期 September 2, 2010
臨床目的 Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them.

Having completed Phase 1 and Phase 2 clinical trials, Provenge is now at the Phase 3 level. One important Phase 3 trial of Provenge has been completed; the current trial is also a Phase 3 study.

If you decide to participate and are eligible, you will be enrolled in the study and randomly assigned to receive either active product or placebo. There are two chances in three that you will receive Provenge. After receiving treatment, you will be monitored at regular intervals until the study endpoints are met. At the end of the trial, men who received placebo will have the opportunity to be treated with active product in another study.

http://clinicaltrials.gov/ct2/show/study/NCT00065442?term=dendreon&rank=4#locn